<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04229992</url>
  </required_header>
  <id_info>
    <org_study_id>100106d</org_study_id>
    <nct_id>NCT04229992</nct_id>
  </id_info>
  <brief_title>Calcium: Magnesium Balance, Microbiota, and Necroptosis and Inflammation</brief_title>
  <official_title>Calcium: Magnesium Balance, Microbiota, and Necroptosis and Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In addition to microbiota-host interaction on inflammatory response, many enzymes, including
      three enzymes critical in gluconeogenesis and transport of amino acids and carbohydrates in
      energy metabolism, are dependent on the Ca/Mg ratio, indicating critical roles of the Ca/Mg
      ratio in carbohydrate fermentation and energy metabolism in bacteria. In pilot metagenomic
      study conducted by the investigators, they found all the significantly changed biologic
      functions within the microbial community caused by a reduction in the Ca/Mg ratio are
      biologically dependent on the Ca/Mg ratio or Mg. It is striking that the functions with
      significant changes in stool samples were centered on the fermentation of carbohydrates and
      energy metabolism while the functions in rectal swabs were related to immune response. Tissue
      also had a distinct profile from stool and swab.

      These findings have very broad clinical and public health significance for many
      inflammation-related diseases or metabolic disorders. Due to the small sample size in the
      pilot study, the investigators plan to confirm these findings using the biospecimens
      collected in the parent study (Personalized Prevention of Colorectal Cancer Trial,
      NCT01105169).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 5, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative PCR for Bifidobacterium and Lactobacillus</measure>
    <time_frame>12 weeks</time_frame>
    <description>Conduct high-throughput quantitative PCR for Bifidobacterium and Lactobacillus in stool, rectal swab, and rectal mucosa samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunohistochemistry for necroptosis-related biomarkers</measure>
    <time_frame>12 weeks</time_frame>
    <description>Conduct immunohistochemistry for necroptosis-related biomarkers in rectal mucosa samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conduct metagenomic analysis of stool, rectal swab, and rectal mucosa samples</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>GG genotype and magnesium treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who have the GG genotype will be assigned to magnesium glycinate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GG genotype and placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants who have the GG genotype will be assigned to placebo group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GA/AA genotype and magnesium treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who have the GA/AA genotype will be assigned to magnesium glycinate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GA/AA genotype and Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants who have the GA/AA genotype will be assigned to placebo group</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Magnesium glycinate</intervention_name>
    <description>Oral administration of magnesium glycinate daily for 12 weeks</description>
    <arm_group_label>GA/AA genotype and magnesium treatment</arm_group_label>
    <arm_group_label>GG genotype and magnesium treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration of identical-appearing placebo daily for 12 weeks</description>
    <arm_group_label>GA/AA genotype and Placebo</arm_group_label>
    <arm_group_label>GG genotype and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Participants from the parent study (Personalized Prevention of Colorectal Cancer Trial,
        NCT#01105169, IRB#100106)

        Exclusion Criteria:

        • Participants did not provide any stool/swab/rectal biopsy sample in the parent study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martha Shrubsole, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 12, 2020</study_first_submitted>
  <study_first_submitted_qc>January 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Martha Shrubsole</investigator_full_name>
    <investigator_title>Research Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

